Abstract
Oral peptide delivery increasingly relies on permeation enhancers (PEs), but how enhancer self-assembly couples to peptide self-assembly and co-assembly remains poorly understood. Here, we investigated the interactions between glucagon-like peptide-1 (GLP-1) analogues and the permeation enhancer sodium caprate (C10), with emphasis on how peptide lipidation and enhancer self-assembly control peptide availability for absorption. A non-lipidated analogue (J211), two mono-lipidated analogues (J229 and semaglutide), and a bis-lipidated analogue (MEDI7219) were characterized by 1H NMR spectroscopy, diffusion NMR, small-angle X-ray scattering (SAXS), circular dichroism (CD) and all-atom molecular dynamics (MD) simulations. In deuterated buffer, the peptides formed distinct oligomeric states with the size ranking semaglutide > J211 > J229 ≈ MEDI7219, while retaining predominantly α-helical secondary structure. C10 underwent a marked colloidal transition with the formulation conditions, forming non-spherical micelles at pD 8.5 and vesicular aggregates at pD 7.4 in fasted-state simulated intestinal fluid (FaSSIF-V2). Under alkaline micellar conditions, C10 associated with all peptides and remodeled the larger oligomers, J211 and semaglutide, by loosening peptide-peptide packing without major changes in global dimensions or helicity. Under near-neutral biorelevant conditions, peptide-C10 co-assembly became strongly peptide dependent. MEDI7219 showed the weakest association with C10 aggregates and retained the largest unbound fraction, whereas semaglutide and J229 had the most bound fraction. This ranking correlated to previously observed intestinal absorption ranking in vivo. These results show that peptide absorption is impacted by the coupled equilibria between peptide self-assembly, enhancer colloidal state, and peptide bound versus unbound fractions.